Sort   by:  
 Page size 
UnknownDosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns.
Not available
S-EPMC5593707 | biostudies-literature
UnknownDosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013.
Not available
S-EPMC5096042 | biostudies-literature
UnknownDosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers.
Not available
S-EPMC4905475 | biostudies-literature
UnknownReview of precision cancer medicine: Evolution of the treatment paradigm.
Not available
S-EPMC7272286 | biostudies-literature
UnknownTargeting fusions for improved outcomes in oncology treatment.
Not available
S-EPMC7050395 | biostudies-literature
UnknownBRAF V600E/V600K Mutations versus Nonstandard Alterations: Prognostic Implications and Therapeutic Outcomes.
Not available
S-EPMC9264327 | biostudies-literature
UnknownCetuximab in Patients with Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Alterations.
Not available
S-EPMC8994415 | biostudies-literature
UnknownCombination high-dose interleukin-2 and nivolumab for programmed cell death-1 refractory metastatic melanoma: a case series.
Not available
S-EPMC9429475 | biostudies-literature
UnknownDosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients.
Not available
S-EPMC5423521 | biostudies-literature
UnknownAdvanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics.
Not available
S-EPMC6290882 | biostudies-literature
Sort   by:  
 Page size